Breaking News, Collaborations & Alliances

Karo Bio, Pfizer Expand RORgamma Research Pact

To discover and develop modulators for the treatment of autoimmune diseases

Karo Bio and Pfizer have extended their existing collaboration to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases through 2014. Pfizer will continue to provide full funding for research costs. Karo Bio is eligible to receive more than $200 million in milestone payments in addition to royalties.

 “We are pleased that Pfizer has chosen to extend our partnership. The decision illustrates the potential of the science behind RORgamma and its application to the treatment of autoimmune diseases. It also reconfirms the potential of Karo Bio’s technology and expertise in the development of drugs targeting nuclear receptors,” said chief executive officer Per Bengtsson.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters